York, Pa. – September 24, 2026 – WellSpan Health has joined the SUPPORT II pivotal trial, becoming the first program in Pennsylvania to evaluate the investigational Supira System during high-risk cardiac procedures.
Loma Linda, Calif. – September 23, 2026 – Loma Linda University Medical Center becomes the first in Southern California to utilize the Supira Medical pVAD system in the SUPPORT II pivotal clinical trial.
Greenville, S.C. – August 25, 2026 – Prisma Health Heart and Vascular Institute has become the first program in the Southeastern U.S. to enroll a patient in the SUPPORT II pivotal study evaluating the Supira System.
Tulsa, Okla. – August 18, 2026 – Supira Medical has partnered with Hillcrest HealthCare System, Oklahoma Heart Institute, and Dr. Kamran Muhammad to bring the SUPPORT II pivotal study to the region, evaluating the investigational Supira System.
NEW YORK, N.Y. – July 31, 2026 - Supira Medical recently highlighted a major clinical milestone on LinkedIn, welcoming Columbia University Irving Medical Center as a trial partner following their successful enrollment of a highly complex subject in the SUPPORT II pivotal study.
SACRAMENTO, Calif., June 26, 2026 – UC Davis Health has launched enrollment for the SUPPORT II Pivotal Study, evaluating the investigational Supira System. This low-profile percutaneous ventricular assist device (pVAD) is designed to provide critical, temporary hemodynamic support for high-risk patients undergoing complex coronary stenting procedures.
ST. CLOUD, Minn. – June 23, 2026 - CentraCare Heart & Vascular recently shared a major clinical milestone on LinkedIn, announcing their program as the first in the Midwest to successfully enroll a patient in the SUPPORT II clinical trial evaluating the investigational Supira System.
LOS GATOS, Calif., April 8, 2026 – Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The trial is designed to support a future PMA submission and represents a critical step toward U.S. market entry.
LOS GATOS, CA., March 26, 2025 – Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company, today announced the successful completion of an oversubscribed Series E financing round, raising $120M to accelerate the company’s mission of transforming the percutaneous ventricular assist device (pVAD) market.
LOS GATOS, Calif., Nov. 21, 2024 – Supira Medical, Inc. (Supira), a Shifamed portfolio company, announced today the initiation and successful patient enrollment in the company’s U.S. EFS. This multi-center prospective, single arm clinical study will evaluate the safety and feasibility of Supira’s innovative low-profile, high-flow percutaneous ventricular assist device (pVAD) in patients undergoing high-risk percutaneous coronary intervention (HRPCI).
